SECTM1 Human Pre-designed siRNA Set A

Cat. No.: S1463025

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Panoramica

SECTM1 Human Pre-designed siRNA Set A contains three designed siRNAs for SECTM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components SECTM1 siRNA-1: 5 nmol (HPLC) SECTM1 siRNA-2: 5 nmol (HPLC) SECTM1 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)

Specifications

Condizioni di conservazione di stoccaggio

Store at -20°C

Spedito in

Ice chest + Ice pads

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Product Line

Prodotti biologici

Application Protocols

Item‑validated protocols are Not specified for this item; the following is a generalized workflow for siRNA use in adherent cells. Adjust to cell type and transfection reagent instructions.

• Materials

  • SECTM1 siRNA set (SKU S1463025), RNase‑free water/TE, transfection reagent, serum‑free medium, complete growth medium, qPCR/Western reagents.

• Reconstitution and stocks

  • Spin vial briefly. Reconstitute in RNase‑free water or TE to 20 µM (example starting point). Vortex gently and incubate 10 min on ice to dissolve. Aliquot and store at −20 °C.

• Complex formation (example)

  • Dilute siRNA to 2× desired final concentration in serum‑free medium.
  • Separately dilute lipid reagent per manufacturer’s recommendation.
  • Combine, mix gently, and incubate 10–20 min at room temperature.

• Transfection

  • Replace cell medium with fresh complete medium (or follow reagent‑specific serum‑free protocol).
  • Add complexes dropwise to achieve 5–20 nM final siRNA. Swirl plate gently.
  • Incubate 24–72 h.

• Assessment

  • Extract RNA at 24–48 h for SECTM1 mRNA qRT‑PCR (normalize to housekeeping genes).
  • Harvest protein at 48–96 h for Western blot/flow/ELISA of SECTM1 protein where antibodies are available.

• Controls

  • Non‑targeting siRNA, positive control siRNA, and mock transfection.

Note: Concentrations/timings above are general guidance and not item‑specific validations.

Biological Roles

This siRNA set targets the human SECTM1 gene (Secreted and Transmembrane 1). The following summarizes biology relevant to interpreting knockdown outcomes (general literature; not product specifications):

• Gene/protein overview

  • SECTM1 encodes a type I transmembrane and secreted protein implicated in immune system interactions, including co‑stimulatory/adhesion roles with hematopoietic cells.
  • Reported interactions include modulation of signaling pathways in immune cell subsets and potential roles in cell migration and communication (literature).

• Expression context

  • SECTM1 transcripts are detected in various tissues, with regulation by inflammatory cues in some cell types (literature). Expression profiles should be verified in the chosen model before knockdown.

• Functional inference with siRNA

  • RNAi‑mediated reduction of SECTM1 allows dissection of its contribution to cell–cell signaling, secretion dynamics, and downstream transcriptional programs.
  • Complementary approaches: rescue with siRNA‑resistant SECTM1 cDNA, CRISPRi/CRISPR KO, or neutralizing tools to confirm on‑target effects.

• Assay readouts

  • Transcriptional changes (RNA‑seq/qPCR), protein abundance (Western/flow/ELISA), and functional phenotypes (chemotaxis, adhesion, cytokine secretion) depending on the biological question.

No medical or clinical claims are made. Researchers should confirm gene IDs (e.g., NCBI/Ensembl accession) and isoform targeting relevant to their model system.

Buffer Applications

While this product is not a buffer, successful use depends on appropriate nuclease‑free buffers for reconstitution, storage, and transfection (general guidance):

• Reconstitution

  • RNase‑free water: convenient for immediate use in cell culture workflows.
  • TE buffer (10 mM Tris‑HCl, 0.1–1 mM EDTA, pH 7.5–8.0): preferred for long‑term stability at −20 °C; EDTA chelates Mg2+ to limit hydrolysis.
  • Target stock concentration: commonly 10–50 µM; exact item recommendation Not specified.

• Working solutions

  • Dilute stocks into serum‑free medium (e.g., Opti‑MEM or equivalent) to form complexes with lipid/polymer transfection reagents; then add to complete medium after 10–30 min complexation.
  • Maintain physiological pH (~7.2–7.4) and isotonicity; avoid high divalent cation levels that may destabilize complexes.

• RNase control

  • Use certified nuclease‑free consumables; wipe benches with RNase decontaminants; include RNase inhibitor in sensitive assays if needed.

• Electroporation buffers

  • Follow manufacturer‑recommended low‑conductivity buffers for electroporation; avoid TE/EDTA in this case as it can interfere with pulsing efficiency.

Item-specific buffer composition, if preformulated, is Not specified for this item; refer to CoA/Spec Sheet.

Green Alternatives

Green chemistry considerations for siRNA experimentation focus on minimizing hazardous ancillary reagents and waste rather than the oligonucleotide itself.

• Opportunities (general)

  • Choose transfection reagents with lower cytotoxicity and improved biodegradability; avoid solvents such as chloroform in lipid complex preparation when possible.
  • Use aqueous buffers exclusively; prepare small, on‑demand aliquots to reduce waste and repeated thawing.
  • Implement micro‑scale transfections (e.g., 96/384‑well) to reduce reagent consumption.

• Buffer and plasticware

  • Employ reusable, autoclavable components where compatible (e.g., glass reservoirs) to reduce single‑use plastics; ensure RNase‑free handling remains uncompromised.

• Energy footprint

  • Consolidate freezer storage (-20 °C) and avoid ultralow (-80 °C) unless required by formulation; maintain efficient sample inventory to reduce door‑open time.

• Comparative view (general)

  • Traditional workflow: High volumes of single‑use plastics and organic solvent‑intensive lipid prep.
  • Greener approach: Ready‑to‑use aqueous lipid reagents, reduced scale, and validated water/TE buffers; no organic co‑solvents.

Note: No item-specific formulation or greener reformulation details are provided for this product; refer to CoA/Spec Sheet for composition if needed.

Pharmaceutical Uses

This product is designated For research use only and is not intended for human or veterinary use, diagnostic procedures, or as a therapeutic.

• Regulatory/compendial status

  • No pharmacopeial monograph or GMP status is stated. Item-specific regulatory grade: Not specified for this item; refer to CoA/Spec Sheet.

• Formulation/excipient context (general)

  • In preclinical research, siRNAs can be formulated with lipid nanoparticles, polymers, or conjugates for delivery studies; however, such uses require dedicated materials manufactured under appropriate quality systems. This catalog item provides research-grade siRNA for in vitro and exploratory in vivo studies under institutional approvals.

• Manufacturing/process utility

  • Can serve as a development tool for screening delivery systems, evaluating sequence potency, and optimizing analytical methods (e.g., LC‑MS oligo characterization, capillary electrophoresis) in non‑clinical settings.

• Documentation

  • For any translational work, sequence disclosure, impurity profiles, endotoxin levels, and stability data are essential; these parameters are Not specified for this item and must be requested via CoA/Spec Sheet.

No therapeutic claims are made for this product.

Physical Properties

Item-specific physico-chemical specifications are not provided for this sequence-defined siRNA set. Where relevant, typical values for synthetic siRNA are provided as general literature guidance only.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet. (Commonly supplied lyophilized or in RNase‑free aqueous buffer.)
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet. (Literature: ~13–15 kDa for a 21‑mer duplex, sequence‑dependent.)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility (general, literature)
  • Freely soluble in RNase‑free water, TE buffer (10 mM Tris, 0.1–1 mM EDTA), or nuclease‑free PBS at typical stock concentrations 10–100 µM.
• pKa/logP/density/RI/UV cutoff: Not typically defined for oligonucleotide mixtures; Not specified for this item; refer to CoA/Spec Sheet.
• UV absorbance (general, literature)
  • Strong absorbance at 260 nm; concentration commonly quantified by A260 using strand‑specific extinction coefficients (sequence‑dependent; Not specified for this item).
• Thermal properties (general, literature)
  • Duplex melting temperature (Tm) depends on sequence/length, salt, and chemical modifications; commonly in the 50–80 °C range for 19–21 bp in standard buffers. Exact Tm: Not specified for this item.
• Formulation excipients/salts: Not specified for this item; refer to CoA/Spec Sheet.

Note: All numerical values above, when mentioned, are general literature expectations for siRNA and not item specifications. Consult the CoA/Spec Sheet for definitive properties of SKU S1463025.

Quality and Grades

• Item-specific grade/purity: Not specified for this item; refer to CoA/Spec Sheet.

• General expectations for synthetic siRNA quality (literature/general)

  • Purity modalities: Desalted, cartridge‑purified (CP), HPLC‑purified, or PAGE‑purified. Higher purity (HPLC/PAGE) reduces off‑target effects and improves potency by removing n−1 species and synthesis byproducts.
  • Identity confirmation: MALDI‑TOF/ESI‑MS for single strands; UV A260 and OD260 units for quantity; optionally IEC/HPLC trace for purity assessment.
  • Duplex annealing QC: Non‑denaturing PAGE or HPLC to verify duplex formation and absence of single‑stranded contaminants.
  • Endotoxin/bioburden: For cell‑based work, low endotoxin is desirable; acceptance criteria vary by vendor. Not specified for this item.

• Stabilizers and formulation (general)

  • Lyophilized oligos may include volatile counterions (e.g., Na+, TEA) or residual salts; some products include RNase‑free buffer components (e.g., TE). Specific excipients for this item: Not specified; refer to CoA/Spec Sheet.

• What the grade implies in practice

  • For gene knockdown studies, HPLC‑purified, duplex‑validated siRNAs typically deliver consistent knockdown with reduced innate immune activation compared to lower‑purity materials.

• Documentation

  • For regulated workflows, retain CoA and sequence documents, including target accession IDs, strand sequences, purification method, and analytical traces (Not specified for this item; request from CoA/Spec Sheet).

Reaction and Applications

As a functional genomics reagent, this siRNA set is used to elicit RNA interference (RNAi) to reduce human SECTM1 mRNA levels in cells.

• Core application (general)

  • Transient knockdown of SECTM1 transcript via RISC‑mediated cleavage using the antisense guide strand.
  • Typical readouts: qRT‑PCR for mRNA reduction; Western blot/flow cytometry/ELISA for protein reduction; phenotypic assays.

• Use cases

  • Target validation and pathway mapping involving SECTM1 in immune cell signaling and adhesion contexts (literature).
  • Controls: Non‑targeting siRNA, positive knockdown control (against a housekeeping or reporter gene), and mock transfection.

• Practical tips

  • Start with 5–50 nM final siRNA per well depending on cell type and delivery reagent; titrate to minimize off‑targets and toxicity (general guidance).
  • Use 2–4 distinct siRNA duplexes (as provided in many “Set A” designs) and analyze concordant phenotypes to strengthen on‑target confidence.
  • Validate knockdown kinetics at 24, 48, and 72 h; some proteins with long half‑lives require longer assessment or repeated dosing.

• Design/Mechanism notes (general)

  • Strand bias optimized by 5′ thermodynamic asymmetry and sequence features to favor guide loading into Ago2.
  • Off‑target mitigation: seed region filtering, low GC content (30–52%), and chemical modifications (if present; Not specified for this item).

• Transfection modalities

  • Lipid‑based, polymer‑based, or electroporation depending on cell type; primary cells often benefit from electroporation or specialized reagents.

Reaction Conditions

Here, “reaction conditions” refer to transfection and RNAi knockdown parameters rather than chemical reactions. The following are general literature guidelines; optimize per cell type and reagent. Item-specific validated conditions are Not specified.

• Cell seeding

  • Plate cells to achieve 30–70% confluence at transfection time to balance proliferation and viability.

• siRNA dose and complexation

  • Typical final siRNA: 5–50 nM (start at 10 nM; titrate).
  • Lipid/siRNA ratio: per transfection reagent instructions; incubate 10–30 min in serum‑free medium to form complexes.

• Incubation

  • Add complexes to cells; after 4–6 h, replace with complete medium if reagent requires. Many modern reagents permit serum‑presence transfection.
  • Assess mRNA knockdown at 24–48 h; protein knockdown at 48–96 h depending on protein half‑life.

• Controls and metrics

  • Include non‑targeting siRNA, positive control siRNA, and mock controls. Monitor cytotoxicity (e.g., CellTiter‑Glo) and transfection efficiency (e.g., fluorescent control siRNA).

• Hard‑to‑transfect cells

  • Consider electroporation with manufacturer‑recommended buffers; adjust pulse parameters empirically.

• Expected outcomes (general)

  • Robust designs typically yield >70% mRNA reduction by qPCR at optimal dose; protein reduction varies with turnover. Actual performance will depend on sequence, cell type, and delivery method.

Safety and Handling

Safety overview for research-use oligonucleotides; defer to the product SDS for authoritative guidance.

• GHS classification and hazard statements

  • Signal word: Not specified for this item; refer to SDS.
  • H‑Statements/Pictograms: Not specified for this item; refer to SDS.
  • siRNA oligonucleotides are generally considered low hazard; handle as laboratory chemicals and biological materials.

• Handling practices (general)

  • Use RNase‑free technique: dedicated pipette tips, gloves, clean work area to avoid RNase contamination and degradation.
  • Wear standard PPE: lab coat, nitrile gloves, eye protection.
  • Avoid aerosol generation when reconstituting or aliquoting; centrifuge briefly before opening vials to collect material.

• Storage incompatibilities and conditions

  • Store at −20 °C as specified by the product data. Protect from repeated freeze–thaw cycles.
  • Avoid exposure to nucleases (RNase, DNase) and extreme pH; maintain samples in nuclease‑free buffers.
  • Keep away from strong oxidizers and UV light which may damage nucleic acids.

• First‑aid overview (general)

  • Skin/eye contact: Rinse with water. If irritation persists, seek medical attention.
  • Inhalation/ingestion: Move to fresh air/rinse mouth and seek medical attention as appropriate per SDS.

• Waste disposal

  • Dispose of aqueous oligonucleotide solutions according to institutional chemical/biological waste procedures; decontaminate surfaces with RNase‑inactivating agents if needed.

Always consult the SDS and institutional EHS guidelines before use.

Solvent Selection

Because this product is an RNA duplex reagent, solvent selection focuses on nuclease‑free aqueous buffers for reconstitution and use, rather than organic solvent systems.

• Recommended diluents (general, literature)

  • RNase‑free water: Widely used for initial reconstitution; compatible with most transfection workflows.
  • TE buffer (10 mM Tris‑HCl, 0.1–1 mM EDTA, pH 7.5–8.0): Enhances stability during long‑term storage by chelating divalent cations that catalyze RNA degradation.
  • 1× siRNA buffer (e.g., 10 mM Tris, 20 mM KCl, 1 mM MgCl2, pH ~7.5): Supports duplex integrity; composition varies by supplier (item‑specific buffer Not specified).

• Avoid

  • Non‑aqueous organic solvents (e.g., DMSO, DMF) are generally unnecessary and may affect transfection; if required for co‑formulations, validate biocompatibility empirically.
  • RNase‑contaminated solutions; always use certified nuclease‑free reagents and plasticware.

• Practical notes

  • Typical stock concentrations: 10–50 µM (general guidance; item‑specific recommendations Not specified).
  • For delivery, siRNA is usually diluted into serum‑free medium for complexation with lipid/polymer reagents, then added to complete medium after 10–30 minutes of complexation.

• Comparison (general)

  • Water vs TE: Water is simplest and often preferred for cell culture; TE offers better long‑term chemical stability at −20 °C but EDTA can interfere with divalent cation‑dependent processes (e.g., some transfection systems). Choose accordingly.

Storage and Reconstitution

• Storage conditions (item-specific)

  • Store at −20 °C (per Product Data). Minimize exposure to ambient temperature. Shipments are on ice chest + ice pads.

• Stability (general guidance)

  • Lyophilized siRNA is typically stable for months at −20 °C if kept dry and protected from light. Aqueous solutions are stable for weeks at −20 °C and days at 4 °C, with improved stability in TE buffer; exact stability for this item is Not specified.

• Reconstitution (general)

  • Use RNase‑free water or TE buffer (10 mM Tris‑HCl, 0.1–1 mM EDTA, pH 7.5–8.0). Target a convenient stock (e.g., 10–20 µM). Item‑specific recommended concentration: Not specified for this item; refer to CoA/Spec Sheet.
  • Allow vial to reach room temperature before opening to avoid condensation. Briefly centrifuge to collect pellet. Gently pipette to dissolve; avoid vigorous vortexing/foaming.

• Aliquoting and freeze–thaw

  • Prepare single‑use aliquots to avoid repeated freeze–thaw cycles. Store aliquots in low‑adhesion, nuclease‑free tubes. Avoid >3 freeze–thaw cycles.

• Working solution handling

  • Keep on ice during setup. Use sterile, nuclease‑free plastics and filtered tips. Discard leftover diluted complexes after use; do not refreeze.

• Documentation

  • Record reconstitution date, buffer, concentration (via A260 if measured), and aliquot map. For lot‑specific instructions or stabilizers, refer to CoA/Spec Sheet.

• Research use note

  • For research use only.

Structure and Identity

Brief overview: SECTM1 Human Pre-designed siRNA Set A is a pool/set of synthetic, double‑stranded small interfering RNAs designed to mediate RNAi‑based knockdown of the human SECTM1 transcript.

• Item-specific identifiers

  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES/InChIKey/CAS/CID: Not applicable to sequence-defined oligonucleotide mixtures; Not specified for this item; refer to CoA/Spec Sheet.

• Structural features (general, literature)

  • Typically 19–21 bp duplex RNA with 2‑nt 3′ overhangs on each strand.
  • Phosphodiester backbone (may include stabilizing modifications in some products; Not specified for this item; refer to CoA/Spec Sheet.).
  • Ribose sugars with 2′‑OH groups characteristic of RNA.
  • Sense (passenger) and antisense (guide) strands designed to be complementary to SECTM1 mRNA (Homo sapiens).

• 2D structure in words (general)

  • Two antiparallel RNA strands aligned via Watson–Crick base pairing (A:U and G:C), forming an A‑form helix segment with short 3′ overhangs (commonly UU or dTdT in many siRNA designs; exact overhangs Not specified for this item).

• Sequence/length information

  • Exact nucleotide sequences, strand lengths, and any chemical modifications: Not specified for this item; refer to CoA/Spec Sheet.

• Target gene context (general)

  • SECTM1 encodes Secreted and Transmembrane 1, a type I membrane/secreted protein implicated in immune modulation and cell–cell interactions (literature).

Synthetic Utility

Not a small‑molecule building block. Traditional organic synthesis applications (e.g., cross‑coupling, nucleophilic substitutions) are not applicable.

• Relevant utility (general, nucleic acid technology)

  • Functions as a sequence‑specific catalyst of mRNA cleavage via the RNAi pathway when delivered to cells.
  • Useful in constructing pathway perturbation experiments and synthetic biology circuits where gene expression modulation is required.
  • Can be combined with reporter constructs (e.g., 3′UTR luciferase reporters) to validate target engagement and seed‑mediated effects.

• Oligonucleotide chemistry context (general)

  • If further chemical modification is required (e.g., conjugation to fluorophores or ligands), this typically necessitates amine/thiol‑modified oligos at defined positions; such modifications are Not specified for this item.

For classical synthetic chemistry workflows, refer instead to appropriate reagents and solvents; this section is included for completeness.

Target Specificity

• Intended target: Human SECTM1 mRNA (Secreted and Transmembrane 1).
• Item-specific details such as exact target transcript IDs (e.g., RefSeq/Ensembl), targeted exons/isoforms, strand sequences, seed regions, and predicted off‑targets: Not specified for this item; refer to CoA/Spec Sheet.

General considerations (literature):

• Specificity determinants include perfect complementarity of the guide strand to the target site, minimized seed matches to unrelated transcripts, and appropriate GC content.
• Using a set of 2–4 independent siRNAs against non‑overlapping regions of SECTM1 and requiring concordant phenotypes strengthens on‑target attribution.
• Rescue experiments with siRNA‑resistant SECTM1 cDNA provide strong confirmation of specificity.
• Off‑target effects can arise from seed‑based interactions; use lower effective doses and, where available, chemically modified siRNAs that reduce off‑targeting (modification status Not specified for this item).